However, in a retrospective, multicenter study of 329 cases of MM in Japanese patients, there were no significant differences between anti-PD-1 monotherapy and combination therapy (PD1 + CTLA4) with regards to ORR (26% versus 29%; P = .26), PFS (median PFS 5.9 months vs 6.8 months; P = .55) or OS (median OS 20.4 months versus 20.1 months; P = .55) (71). The gene discussed is CTLA4; the disease is Miyoshi myopathy.